A new oral immunotherapy could change how peanut allergy is treated, targeting the gut to retrain the immune system and reduce the risk of life-threatening reactions. INP20’s nanoparticle technology promises a safer, more precise approach that could replace lifelong avoidance with lasting tolerance.
Sign Up for Exclusive Access
To access this content please login, create an account or continue as a guest. If you choose to login or create an account you won't have to complete the registration form, and you'll be able to access most of our content free-of-charge.
Login Become a Member